

- Tan, Meng** (Canadian Diabetes Association)  
Patent Act (amdt.)(Bill C-22), 14:3, 47-54
- Tardif, Monique B.** (PC—Charlesbourg; Parliamentary Secretary to Minister of National Health and Welfare; Acting Chairman)  
Bio-medical research, 10:45-6  
Biotechnology industry, 12:16  
Brand name drugs, 1:35; 7:18; 12:15, 41; 15:30  
Canadian Health Coalition, 7:18  
Chrétien, references, 10:45  
Diabetes, 15:67  
Drug patents, 16:45-6, 51, 56-7  
Drug plans, 11:65-6; 12:64; 15:81-2  
Drug Prices Review Board, 3:72-3; 12:73  
Drugs and pharmaceuticals, 1:35-6; 5:23; 10:19, 29; 11:49-50, 65; 12:27, 73; 15:82-3  
Drugs and pharmaceuticals industry, 3:62-3; 12:73; 15:16, 68  
Generic drugs, 3:26-7, 62; 5:24; 9:53; 10:18; 12:41, 72-3; 15:66-7, 83, 98-9  
Health care, 9:38-9; 10:29-30; 15:17, 29-30  
High technology centres, 5:44  
McMaster University Faculty of Health Sciences, M., 10:4  
New Democratic Party, 10:28  
Patent Act, 11:65  
Patent Act (amdt.)(Bill C-22), 1:34-6, 42; 3:26-7, 62-3, 72-3; 4:11-2, 20-1, 23-4, 43-4; 7:17-8; 9:38-9, 53; 10:4, 18-9, 28-30, 45-6, 48-9; 11:33, 35-8, 48-50, 64-6; 12:15-6, 26-8, 41-2, 64, 72-4; 15:16-7, 29-30, 66-8, 81-3, 98-9; 16:44-6, 51, 54-7  
Procedure and Committee business  
Acting Chairman, taking Chair, 6:5  
Bills, 10:49; 11:33  
M. (Orlikow), 11:35  
Amdt., 11:37-8  
Organization meeting, 1:8  
Questioning of witnesses, 6:11-2  
Witnesses, M. (White), 4:11-2, 20-1  
Pharmacists, 12:64  
Quebec Federation of Senior Citizens, 12:26-7  
Universities, 5:43
- Taxation** *see* Income tax
- Technology** *see* High technology centres
- Technology transfer, 14:8**  
*See also* Bio-medical research
- Terry Fox Medical Research Foundation**  
Brand name drug companies' contribution, 3:69-70  
Legislation, Bill C-22 supporting, 15:83  
Pacific Isotopes and Pharmaceuticals, funding, 6:37
- Thalidomide** *see* Drugs and pharmaceuticals industry—Research and development, "Me too" emphasis
- Thatcher, Right Hon. Margaret**  
References, 1:25
- Thompson, Ian** (Individual presentation)  
Patent Act (amdt.)(Bill C-22), 9:10-22
- Timolol** *see* Drugs and pharmaceuticals
- Torcan** *see* Drugs and pharmaceuticals industry—Fine chemicals manufacturing
- Toxic shock syndrome** *see* Diseases—Infectious
- Toxicology** *see* University of Toronto
- Transfer pricing** *see* Drugs and pharmaceuticals industry
- Trudeau, Raymond** (Canadian Chamber of Commerce)  
Patent Act (amdt.)(Bill C-22), 8:3, 28
- Tuberculosis** *see* Health care—Hospitals, Drug therapy alternatives
- Unemployment insurance** *see* Drug plans—Access
- Unions**  
Members' dues, siphoning to United States, 12:72  
*See also* Biotechnology industry—Research and development; Nurses; Public Service Alliance of Canada—Political
- United Kingdom** *see* Biotechnology industry—Legislation; Brand name drugs—Exclusivity period from imports, International standards; Drug Prices Review Board—Regulatory powers; Generic drugs—Royalty payments
- United Senior Citizens of Ontario** *see* Witnesses
- United States**  
Lawsuits, new drug research, inhibiting, 6:46  
Supreme Court *see* Biotechnology industry—Patent law principles  
*See also* Ayerst Laboratories—Canadian origin; Biotechnology industry—Legislation; Brand name drugs; Drug plans; Drugs and pharmaceuticals; Drugs and pharmaceuticals industry—Market environment; Free trade, Canada-United States negotiations; Generic drugs; Health care; Merck Frost Canada Inc.—Canadian origin; Senior citizens; Unions
- United Way**  
Legislation, Bill C-22 effect, 11:55
- Universities**  
Alberta, research projects, current, 5:43-4; 11:39  
Brain drain, 6:35, 44-5; 11:40  
Medical schools, Bill C-22 support, 12:29-30  
Public funding/private benefits, moral issue, 6:43; 12:65  
Research and development  
Brand name drug companies' pledge, 14:8  
Clinical/basic research, extent, 11:16; 12:65-6, 71-2, 76; 13:8, 46; 14:13, 48-9; 15:13  
Compulsory licensing, effect, 8:57  
Government/industry funding, eroding, 6:34-5, 44-5; 11:7, 17; 12:30; 13:10, 25; 14:17-8, 32, 59, 65; 15:8, 12, 48, 97  
Patent protection lacking, 11:39; 16:84-5  
Private sector "matching" policy, 14:47-8, 50-1  
Requirements, 12:33  
Science Council of Canada proposal, 15:74  
*See also* Universities—Alberta  
*See also* Drugs and pharmaceuticals industry—Research and development; High technology centres
- University of Toronto**  
Human toxicology centre, industry funding, Bill C-22 contingent, 6:35-6
- University of Western Ontario**  
Mice experiments, Interleuken 2, 8:47
- University Research Incentive Fund**  
Ontario, provincial government share, 12:30
- Vaccines** *see* Drugs and pharmaceuticals industry—Self-insurance
- Valium** *see* Drugs and pharmaceuticals
- Vennat, Manon** (Montreal Board of Trade)  
Patent Act (amdt.)(Bill C-22), 10:3, 5-8, 10-1, 13, 15, 17-9
- Venture capital** *see* Altamira; Biotechnology industry
- Walker, Michael** *see* Drugs and pharmaceuticals—Costs/prices